| Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. | None |
| The neu (c-erbB-2) oncogene. | None |
| A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. | None |
| Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. | None |
| Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. | None |
| [Polymorphic changes in cellular phenotype during hyperexpression of the NEU proto-oncogene]. | None |
| Transformation of mouse mammary epithelial cells with the Ha-ras but not with the neu oncogene results in a gene dosage-dependent increase in transforming growth factor-alpha production. | None |
| Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. | None |
| Pattern of expression of c-erbB-2 oncoprotein in human fetuses. | None |
| Essential activating sequence exists in the extracellular domain of HER2. Disruption of this sequence disables HER2 dimerization loop, blocks subsequent activation of HER2-driven oncogenic signaling, and generates a dominant-negative form of HER2. | None |
| EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. | None |
| ErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling. | None |
| Data indicate that high proto-oncogene protein HER-2 (HER2) and low estrogen receptor alpha (ESR1) mRNA levels are required for achieving trastuzumab response. | None |
| HER2 missense mutations have distinct effects on oncogenic signaling and migration. | None |
| HER2 missense mutations have distinct effects on oncogenic signaling and migration. | None |
| Data indicate that the combination with the HER-2 proto-oncogene protein (HER2) inhibitor lapatinib and the inhibition of mTOR serine-threonine kinase (mTor) affords the highest degree of synergy. | None |
| PKG II inhibits EGFinduced activation of HER2 through binding with and causing threonine 686 phosphorylation of this oncogenic protein. | None |
| Immunohistochemical detection of the c-erbB-2 proto-oncogene product in normal, benign and malignant cartilage tissues. | None |
| Studies indicate that overexpression of the HER2 proto-oncogene protein (HER2) may be found without the amplification of the HER2 gene, and HER2 gene amplification can occur without overexpression of the HER2 protein. | None |
| Her2 oncogene transformation has a role in enhancing 5-aminolevulinic acid-mediated protoporphyrin IX production and photodynamic therapy response | None |